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INTRODUCTION
Chronic lymphocytic leukemia (CLL)
is the most common form of adult
leukemia in the Western world. CLL is a
disease of long-lived B cells that are ca-
pable of proliferating upon appropriate
stimuli and accumulate in the peripheral
blood (PB), bone marrow (BM) and
lymph nodes (LNs) (1–4). There is
emerging evidence that the tumor mi-
croenvironment influences the survival
and drug resistance of CLL cells (5) and
other cancer cells (6,7), playing a critical
role in the growth, invasion and progres-
sion of a variety of malignancies, includ-
ing hematological malignancies. CLL
cells rapidly undergo apoptosis in vitro,
but survive for a longer time in vivo, thus
underscoring the role of the microenvi-
ronment in the growth and survival of
CLL cells (8). Several studies have used
in vitro culture systems involving T cells,
stromal cells, follicular dendritic cells,
nurselike cells (NLCs) and CD40 engage-
ment to study the role of the microenvi-
ronment in CLL (9–11). The presence of
stromal components in the microenviron-
ment, such as NLCs, protects CLL cells
from death and enhances the expression
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of genes related to chemokines and B-cell
receptor (BCR) signaling (9,12). Further-
more, CLL cells proliferate in vitro in the
presence of stroma and soluble media-
tors such as interleukin (IL)-2 or IL-10
(13). Although these in vitro culture sys-
tems simulate the in vivo microenviron-
ment to a certain extent, studying CLL
cells directly from in vivo sites will more
accurately define the molecules associ-
ated with vital functions in vivo.
Emerging evidence suggests that
 clinical/biological heterogeneity in CLL
is due to tissue microenvironment-
 influenced variation in proliferation and
survival (8). Only a few studies have re-
ported the importance of PB, BM and LN
microenvironments in CLL (14–19). This
study enhances the information by pro-
viding a comprehensive list of gene sig-
natures of CLL cells from three distinct
tumor microenvironments, such as PB,
BM and LN not reported previously, and
associates these signatures to clinical
markers that predict disease progression
and clinical outcome.
MATERIALS AND METHODS
CLL Patient Information and Sample
Collection
PB (n = 20), BM (n = 18) and LN (n =
15) samples were collected from CLL pa-
tients with informed consent using an in-
stitutional review board–approved proto-
col at University of Nebraska Medical
Center. Of these, seven PB and BM sam-
ples, two PB and LN, and three BM and
LN paired samples were from the same
patient. Only untreated patients and pa-
tients who had not received treatment in
the prior 6 months were included in this
study. The patient characteristics are de-
scribed in Results.
Isolation and Characterization of CLL
Cells
CLL cells from PB and BM were iso-
lated and immunophenotyped by flow
cytometry by using the following com-
binations of antibodies as described pre-
viously (20). Briefly, wherever needed,
antibody cocktail for B-cell enrichment
(RosetteSep; Stemcell Technologies Inc.,
Vancouver, BC, Canada) was used to
purify the B-CLL cells from PB and BM
samples. This cocktail kit binds and
eliminates erythrocytes and other white
blood cells except B cells by subsequent
density gradient centrifugation using
LymphoPrep and isolation of purified 
B cells (>90%) from the interface. Frozen
LN samples were obtained from the
University of Nebraska Medical Center
tissue bank. CLL cells were identified in
the 10-micron sections of these LNs by
using immunohistochemical techniques
to localize CD19+ and CD5+ cells. Fifteen
to twenty (8–10 microns thick) sections
were prepared from each LN on mem-
brane-coated glass slides. These slides
were prepared at 4°C, and these sections
were immediately fixed with ice-cold
acetone and stained with cresyl violet
(LCM Staining Kit;  Ambion/Life Tech-
nologies, Carlsbad, CA, USA) for 30 s.
The corresponding CD19+ and CD5+
areas were laser microdissected by
using the laser capture microdissection
technique (Leica Microsystems Inc.,
Wetzlar, Germany), specially focusing
on areas with >90% CLL cells, which
were identified and microdissected.
Areas containing stromal cells either
were excluded or burnt out by using a
laser, thus further decreasing the stro-
mal cell components. The microdis-
sected cells were immediately processed
for isolation of RNA to avoid degrada-
tion of RNA.
Cytogenetic Analyses
The cytogenetic analyses including flu-
orescent in situ hybridization (FISH) were
performed by the Human Genetics Insti-
tute at University of Nebraska Medical
Center as described earlier (21). Chromo-
some 11q deletion, 17p deletion and tri-
somy 12 were considered as the poor out-
come group, whereas normal karyotype
and 13q deletion were grouped as the
better outcome group (22).
In Vitro Stromal Cell Culture System
To simulate the in vivo microenviron-
ment, an in vitro stromal culture system
was used to study the survival and pro-
liferation of CLL cells in vitro as de-
scribed earlier (25). Freshly isolated 
primary CLL cells were cocultured on
the mouse-derived OMA-AD or
human-derived HMEC stromal feeder
cell layer in the presence of RPMI with
10% fetal bovine serum medium for 48–
72 h, and survival and proliferation of
CLL cells were determined by flow cy-
tometry.
Gene Expression Analyses
Total RNA was extracted from CLL
cells by using TRIzol (Invitrogen/Life
Technologies) as described earlier (20).
RNAs (approximately 0.5 μg per sample)
from CLL cells were used for gene ex-
pression profiling on a DNA microarray
chip (MWG Biotech, Ebersberg, Ger-
many, Human 30K oligo set B) consisting
of 50-mer oligonucleotide representing
10,000 different genes. Stratagene refer-
ence RNA, labeling of cDNA, hybridiza-
tion procedure and locally weighted
 scatterplot smoothing (LOWESS) inten-
sity- dependent normalization were im-
plemented using standard procedures,
Gene Pix 6.0 and BRB Array Tools as de-
scribed previously (20). Differential
mRNA expression in PB-, BM- and LN-
CLL cells was evaluated by using a ran-
dom variance t test (p < 0.005), signifi-
cance analysis of microarrays (false
discovery rate [FDR] <10%) and gene set
enrichment analysis computational pro-
gram in conjunction with BRB array tools
(version 4.2.0-Beta) (23,24). Cluster and
TreeView programs were also used in the
analyses (Eisen Laboratory, University of
California, Berkeley, CA, USA).
Validation of Significant Genes Using
Real-Time Quantitative Polymerase
Chain Reaction
SYBR Green real-time polymerase
chain reaction (PCR) was used to further
confirm differential gene expression be-
tween CLL groups. Complementary
cDNAs were mixed with primers and
Power SYBR Green PCR Master Mix
(Applied Biosystems/Life Technologies)
as previously described (25).
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Detection of Surface and Intracellular
Markers Using Flow Cytometry
Cells were stained with CD19-FITC
(fluorescein isothiocyanate) marker to
specifically analyze the proportion of
CLL cells. Further, surface apoptotic
marker annexin V, intracellular  phospho-
Syk and proliferation marker Ki-67 were
detected by using annexin V/PI staining,
 “phosphoflow” (BD Phosflow) and Ki-67
staining, respectively, following the man-
ufacturer protocol (BD Biosciences, San
Jose, CA, USA). For analyses, a BD FAC-
Star Plus flow cytometer (BD Bio-
sciences) was used.
Identification of Key Signaling
Molecules Using Eμ-TCL1 Transgenic
Mouse
TCL1 transgenic (TCL1-tg, n = 3), a
mouse model for CLL, and C57BL/6
control (n = 3) mice were a generous
gift from our collaborator Rene
Opavsky at University of Nebraska
Medical Center. These mice were reared
and maintained at a pathogen-free ani-
mal facility in the University of Ne-
braska Medical Center. LN and spleen
tissues were harvested from these mice
to study key molecules in the leukemic
cells. All experiments were performed
in accord with the approved protocol
by the Institutional Animal Care and
Use Committee of University of Ne-
braska Medical Center.
Evaluation of Expression of Key
Molecules at the Protein Level Using
Immunohistochemistry
To validate our findings from the gene
expression analyses, we examined the
expression levels of phosphor-SYK and
phosphor-p-65, the major molecules as-
sociated with BCR and nuclear factor
(NF)-κB signaling using immunochem-
istry. Briefly, the 5- to 10-micron histolog-
ical sections of the LNs from CLL pa-
tients and lymphoid tissue from TCL1
transgenic mice were stained with p-SYK
(catalog number PAB0623, 1:200 dilution)
or p-P65 (catalog number AB28810, 1:50
dilution). A Leica Bond Polymer Refine
Detection Kit (Leica Microsystems Inc.)
was used to visualize the cells positive
for these two primary antibodies, as de-
scribed in the manufacturer protocols.
Statistical Analyses
For the identification of differentially
expressed genes, a significant analysis of
microarray was used. To identify the
 tissue-specific gene signatures, analysis
was performed using a random variance
F test with a p value of 0.01 and FDR of
0.08. Most of the analyses were per-
formed at p < 0.05 and FDR < 0.25, un-
less specified otherwise. The Kaplan-
Meier method using the log-rank test
was used to study the association of gene
expression or clinical parameter with the
clinical outcome as done previously
(22,25). Time to treatment among CLL
patients was used as an outcome and de-
fined as the time period in months be-
tween diagnosis and initiation of the first
treatment regimen.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Patient Characteristics
We performed GEP on 20 PB, 18 BM
and 15 LN specimens from 37 consenting
CLL patients. The clinical characteristics
of these 37 patients are shown in Supple-
mentary Table S1. The patients included
25 males (67.5%) with a median age of 55
years and 12 females (32.5%) with a me-
dian age of 65 years. The median age of
the patients at the time of diagnosis was
59 years (range 29–85). Of the 37 patients,
GEP was obtained from paired BM/PB (n
= 7), BM/LN (n = 3) and LN/PB (n = 2)
samples from the same patient. We also
tested an additional cohort of 40 PB sam-
ples (20) from CLL patients to validate
the biologic and clinical findings.
Mouse- and Human-Derived Stroma
Supports CLL Cell Growth
To investigate the influence of the mi-
croenvironments on the survival and
growth of CLL cells, we used an in vitro
system and cocultured CLL cells with
stromal cells using BM-derived 
(OMA-AD) and endothelial-derived
(HMEC) stromal cell lines (Figure 1A).
Consistent with our previous observa-
tion, cocultured CLL cells showed a ten-
dency of higher proliferation, as mea-
sured by a 1.5- and 3.5-fold increase in
Ki-67–positive CLL cells, in OMA-AD
and HMEC cocultured conditions, re-
spectively. Consistent with this observa-
tion, prolonged survival was observed
with significantly (p < 0.0001, p < 0.005)
reduced frequency of early apoptotic
(positive for annexin V only) and late
apoptotic (positive for annexin V/PI) co-
cultured CLL cells under both types of
stromal cell systems (Figure 1B). Interest-
ingly, cocultured CLL cells demonstrated
significant (p < 0.05) upregulation of
NF-κB target genes, for example, IL-6,
BCL2 and TRAF1, as measured by quan-
titative real-time (qRT)-PCR (Figure 1).
Thus, these studies indicate the impor-
tance of a compact stromal microenvi-
ronment usually found in tissues such as
LNs in providing prosurvival and pro-
proliferation signals to CLL cells.
Gene Expression Signature of 
PB-, BM- and LN-CLL Cells
In our initial analyses using unsuper-
vised hierarchical clustering of ~9,900 ge-
netic probes on GEP of CLL cells from
three in vivo sites, we observed that CLL
cells from the three anatomic sites did
not form tight clusters, indicating hetero-
geneity within the tissue compartments
(Figure 2A). However, of the samples
from the three lymphoid compartments,
LN specimens (n = 15) clustered into two
major nodes, whereas PB-CLL and BM-
CLL samples were interspersed ran-
domly, suggesting more homogeneity of
gene expression among LN-CLL cells
compared with PB-CLL and BM-CLL
samples. These two groups of LNs were
not distinguished from each other based
on the known chromosomal abnormali-
ties, high versus low CD38 expression,
presence or absence of lymphadenopathy
and/or time to treatment. Therefore, to
obtain tissue-specific CLL gene signa-
tures, supervised differential gene ex-
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pression analysis was performed using a
random variance F test (p < 0.01, FDR <
0.08). With this approach, we observed
~1,000 genes that were differentially ex-
pressed among PB-, BM-, and LN-CLL
cells (Figure 2B). A detailed analysis
showed that LN-CLL cells overexpressed
various gene signatures involved in
B-cell activation (CD40, SYK, TACI,
BCMA), chemokine receptor signaling
(CXCL13, CXCL14, CCL21) and induction
of immune tolerance (CAV1, BATF, TTK,
INDO1, IL10, CAMLG) (Figure 2B, Sup-
plementary Figures S1A, B). Further,
genes associated with mitogen-activated
protein kinase (MAPK)-, phosphatidyli-
nositide 3-kinase/protein kinase B
(PI3K/AKT)- and NF-κB–signaling path-
ways were distinctly expressed in CLL
cells from PB, BM and/or LN sites. Ad-
ditionally, transcripts involved in B-cell
activation and differentiation (CXCR4,
FCER2, AKT2) were noted in the PB sig-
nature, whereas cytoskeleton and cell ad-
hesion molecules (KRT19, KRT18,
COL10A1) were noted in the BM-CLL
signature (Figure 2B, Supplementary Fig-
ure S1).
Differentially Expressed Genes
Associated with the Seven Major
Signaling Pathways
We next analyzed gene expression of
CLL cells from different sites by using
gene set enrichment analysis (24) to 
identify enriched cellular pathways/
 signatures. We observed >100 enriched
cellular pathways/signatures among the
CLL cells from LN, BM and PB. These
analyses showed that LN-CLL cells were
enriched in gene signatures related to
tumor progression, and immunosuppres-
sion or immune tolerance, suggesting
that the LN microenvironment is con-
ducive to tumor cell growth while in-
hibiting host immune response against
CLL (Table 1; Supplementary Figures
S2A, B, D, E). Additionally, the poor
prognostic IGHV3-21 gene signature (26)
consisting of genes associated with a
worse outcome in CLL was enriched in
Figure 1. Survival, proliferation and upregulation of the NF-κB–associated genes in cocultured CLL cells in vitro with human- or mouse-de-
rived stromal cells. Analyses of cell survival, proliferation and change in expression of key genes in primary CLL cells cocultured with
mouse BM-derived OMA-AD and human endothelial-derived HMEC stromal cells at 72 h. The results were analyzed using a Student t test
(p < 0.05). (A) Measurement of the proliferation of CLL cells (n = 6) cocultured on stroma using Ki-67 staining. (B) Measurement of the sur-
vival of CLL cells (n > 7) cocultured on stroma using annexin V staining. (C) Validation of the upregulation of key genes in CLL cells 
(n = 6) cocultured on stroma using real-time PCR.
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Figure 2. Unsupervised and supervised clustering of gene expression profiles of PB-CLL (n = 20), BM-CLL (n = 18) and LN-CLL (n = 15) cells
in vivo from patients. (A) Unsupervised hierarchical clustering of genes obtained from CLL enriched lymphoid compartments. (B) Super-
vised clustering of genes of CLL cells isolated from different lymphoid compartments (p < 0.01, FDR < 0.08).
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LN-CLL compared with PB-CLL (Table 1,
Supplementary Figure S2F). BM-CLL
showed enrichment of gene signatures
involved with cell cycle and antiapo -
ptotic compared with PB-CLL (Table 1,
Supplementary Figure S2C).
From the several enriched pathways
differentially expressed among PB-, BM-
and LN-CLL cells, seven major path-
ways/functional signatures relevant to
CLL and/or B-cell biology were identi-
fied based on gene ontology: BCR signal-
ing, B cell–activating factor/a prolifera-
tion-inducing ligand (BAFF/APRIL)
signaling, MAPK signaling, PI3K/AKT
signaling, NF-κB signaling, chemokine
ligands/receptors and tolerance (Figure
3A). Further, the expression of critical
genes in these signatures was validated
by qRT-PCR. Only genes with significant
differential expression (t test, p < 0.05) are
shown in Figure 3. Several transcripts in-
volved in BCR signaling (for example,
SYK, BTK and VAV2) and BAFF/APRIL
signaling (for example, BAFF, BCMA and
TRAF2) that were significantly expressed
in LN-CLL by microarray were con-
firmed by qRT-PCR (Figure 3B, Supple-
mentary Table S2), thus suggesting acti-
vated BCR and BAFF/APRIL signaling in
LN compared with PB or BM. Despite the
absence of probes for ZAP-70 on our mi-
croarray, we studied its expression using
real-time PCR and found that it was sig-
nificantly (p < 0.05) overexpressed in LN-
CLL compared with PB-CLL and BM-
CLL (Figure 3B). Similarly, transcripts of
different genes associated with NF-κB
(IL6, NF-κBIL1, RELB, STAT1), MAPK
(MAP3K2, MAP2K5, MAP2K11, MAPK4)
and PI3K/Akt (AKT1, 4E-BP1, PDK1,
IGFBP6) pathways that were overex-
pressed in CLL cells from the different
microenvironments (Figure 2, Supple-
mentary Figure S1) were validated by
qRT-PCR (Figure 3B). These pathways
play an active role in the proliferation of
CLL cells. It is likely that CLL cells in dif-
ferent microenvironments use different
molecules for survival/ proliferation.
From the GEP data, we surmised that
CLL cells use chemokine ligands/
 receptors for migration; for example,
CXCR4 and CCR7, were significantly
overexpressed in PB-CLL and their cog-
nate ligands CXCL12 and CCL21 were
overexpressed in BM and LN microenvi-
ronments (Figures 2B and 3). These data
are consistent with chemokine receptor/
ligand gradients governing migration of
CLL cells into different microenviron-
ments. Interestingly, genes associated
with immune tolerogenesis (CAV1,
MCM3, BATF) were uniquely overex-
pressed in LN-CLL compared with BM-
CLL and PB-CLL (Figures 2B and 3, Sup-
plementary Figure S1), indicating the LN
microenvironment plays a role in induc-
ing immunological tolerance of CLL
cells. The role of this tolerogenic signa-
ture in LN is recently validated by us
(38). Together, these results elucidate the
genes overexpressed in LN-CLL and in-
dicate that the microenvironment influ-
ences CLL cell behavior. To further con-
firm the LN microenvironment-induced
effects on CLL progression, the expres-
sion of previously reported drug resist-
ance–related genes was studied (27,28).
Among the genes we analyzed, ABCC6,
HSP70 and HSP90 were significantly
overexpressed in LN-CLL compared
with BM-CLL and PB-CLL cells, indicat-
ing that the LN microenvironment also
induces drug resistance in CLL (data not
shown). We validated the expression of
phosphor-SYK (BCR signaling) and p-
P65 (NF-κB signaling) in leukemic cells
from TCL1 transgenic mouse and pa-
tients’ LN by using immunohistochem-
istry (Figure 4). LN tissue was harvested
from TCL1-Tg mice at 37 wks, at which
time accumulation of leukemic B-cells
(B220/CD5+) occur in lymphoid organs
(40). A high percentage of leukemic B
cells from LN of TCL1-Tg mice were
found to be positive for p-SYK (~50%)
and p-P65 (~99%) (Figure 4, panel I: A–
F). The expression pattern of p-SYK and
p-65 in leukemic cells from spleen tissue
of TCL1-Tg mice at 37 wks were highly
similar with that of LN from the mice
(data not shown). Furthermore, the ex-
pression of these key signaling molecules
were investigated in patient LNs. As ex-
pected, a high percentage of CLL cells
were positive for p-SYK (~90%) and p-
P65 (100%) signaling molecules, validat-
Table 1. Enriched pathways observed by using gene set enrichment analysis.a
LN enriched BM enriched PB enriched
LN versus BM Immune suppressive (Sasaki ATL Up), Cancer B-cell differentiation (Martinelli Ifns No comparison made
progression (Cancer Neoplastic Meta Up) Differentiation, Haddad HSC CD7 Up)
LN versus PB Immune suppressive (Sasaki ATL Up), Cancer No comparison made Immunity and inflammation 
progression (Cancer Neoplastic Meta Up), (Passerini_Immune, Passerini 
B-CLL poor prognosis (IgVH3–21 Gene Inflammation)
signature)
BM versus PB No comparison made B-cell differentiation (Martinelli Ifns Cell cycle regulatory (Cell
Differentiation, Haddad Hsc Cd7 Up), Cycle pathway, Ageing Brain
Cell cycle and antiapoptosis (Yagi Up, G1 To S Cell Cycle 
AML_Prognosis) Reactome)
aThe words in parentheses in this table are names of signatures, which pop up through GSEA analyses on the GSEA website. Each name
indicates a specific gene set at the GSEA website.
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Figure 3. Mean expression of genes associated with seven major signaling pathways and validation of expression of key genes using
real-time PCR. (A) Supervised cluster analyses of differentially expressed genes (p < 0.05) associated with seven major signaling path-
ways. The mean expressions of these significant genes are shown among PB, BM and LN cells. (B) Confirmation of the differentially ex-
pressed genes among PB-CLL, BM-CLL and LN-CLL using real-time PCR. Expression of the selected genes from each major pathway was
studied by using real-time PCR. Significant differences in expression levels between PB-CLL, BM-CLL and LN-CLL were determined by
using the Student t test (p values when comparing with LN cells: *p < 0.05, **p < 0.01, #p < 0.005, ##p < 0.001; p values for comparison
with PB is denoted with *p and comparison with BM is denoted as *b). First row: BCR signaling: SYK, BTK, ZAP70; second row: BAFF/APRIL
signaling: BAFF, BCMA, TRAF2; third row: MAPK signaling: MAP2K6, CAMLG, STAT1; fourth row: PI3K/Akt pathway: PDK1, IGFBP6, AKT1; fifth
row: NF-κB pathway: NF-κBIB, FCER2, CCND2; sixth row: chemokine ligands/receptors: CXCR4, CCL21, CCR7; seventh row: tolerogenic
signature: CAV1, MCM3, IDH; microarray analyses had shown all genes were differentially expressed among PB-CLL (n = 20), BM-CLL (n =
18) and LN-CLL (n = 15). 
ing the expression signature in LN-CLL
cells (Figure 4, panel II: C, D, F). Alto-
gether, CLL cells from a defined struc-
tural microenvironment such as LN ap-
pears to have activated molecules of
signaling pathways that are known to
drive cell survival and proliferation.
Differential Expression of Key Genes in
Prognostic Groups in PB-CLL, BM-CLL
and LN-CLL
We correlated gene expression profiles
with three clinical parameters including
chromosomal abnormalities, bulky lym-
phadenopathy (BLA) and time to treat-
ment in CLL cells from each tissue com-
partment to identify gene signatures that
may be responsible for adverse clinical
outcome.
Lymphadenopathy. GEPs derived from
PB samples were compared in patients
with (n = 9) or without (n = 11) BLA. Pa-
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tients with BLA had a significantly higher
number (n > 400) of upregulated genes
(Figure 5A), and among these BCR signal-
ing (CD79b, CD72, SYK, BTK, BLNK) was
the dominant signature in this subset of
cases. To confirm BCR activation, phos-
phorylated-SYK (p-SYK) was measured
by using flow cytometry in four samples
from CLL patients with BLA and five
from patients without BLA. Expression of
p-SYK was significantly (p < 0.05) higher
in the CLL samples with BLA compared
with those without it (Figure 5B).
Chromosomal abnormalities. We per-
formed differential expression between
PB samples of patients with high-risk
cytogenetic abnormalities [del(11q),
del(17p) and trisomy12, n = 7] versus
cases without these abnormalities (n =
12). Significantly higher expression of
genes associated with BCR signaling
and cell activation (BTK, AKT2, CD83,
LAG3) correlated with the higher risk of
genetic abnormalities (Supplementary
Figure S3A). A similar observation was
observed in BM-CLL GEP analysis (Sup-
plementary Figure S3B). In addition, we
observed that the transcripts of
chemokine ligand CCL3 significantly
correlated with higher risk of cytoge-
netic abnormalities in both BM-CLL (p <
0.05) and LN-CLL (p < 0.05) specimens
(Figure 5C). These observations are con-
sistent with our validation cohort of PB-
CLL samples (n = 40), where high CCL3
mRNA expression was also significantly
(p = 0.02) associated with a shorter time
to treatment (Figure 5D).
Time to treatment. Transcripts encod-
ing genes associated with B-cell activa-
tion (CD69) were significantly associ-
ated with short time to treatment (<12
months; n = 9) compared with the group
with a longer time to treatment (>12
months; n = 10) (Supplementary Figure
S3C), consistent with the above observa-
tion. A subset of genes related to apo-
ptosis (CASP6, BID, and CASP4) was
underexpressed in LN cases with
shorter interval of treatment, suggesting
that antiapo ptotic functions dominate in
this group (Supplementary Figure S3D).
Overall, these observations indicate
that chronic BCR signaling is a dominant
pathway in CLL, as indicated by higher
expression of BTK and AKT2, CD69 and
phosphorylated SYK (p-SYK) in the chro-
Figure 4. Confirmation of expression of pSyk and p-P65 in lymphoid tissue of a TCL-1 transgenic mouse model and human patients using
immunohistochemistry. Panel I: A representative immunohistochemistry of LN tissue from TCL-1 transgenic mouse. Lymphoid tissue were
collected at wk 37 from the mouse and stained for B220 (A), CD5 (B), p-P65 (C), pSYK (D) and control antibody (E). Average of percent
positive B220/CD5+ cells for pSYK and p-P65 from the transgenic mice (n = 3) is shown (F). Panel II: A representative immunohistochemistry
of LN from CLL patient. LN tissue from CLL patient is stained with CD5 (A), CD19 (B), p-P65 (C), p-SYK (D) and control antibody (E). Average
of percent positive CD19/CD5+ CLL cells for p-SYK and p-P65 from patient LNs (n = 3) is shown (F).
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mosomal abnormalities, time to treatment
and BLA prognostic groups, respectively,
and therefore may be a valuable prognos-
tic and therapeutic target in CLL.
DISCUSSION
We and others have studied the role of
microenvironments in survival/prolifera-
tion and migration of CLL cells using in
vitro culture systems (25,29). However, in
vitro culture systems have limitations and,
therefore, we analyzed gene expression in
CLL cells directly from these in vivo mi-
Figure 5. Correlation of differential gene expression with a prognostic indicator such as BLA and validation of expression of key molecules such
as pSyk and CCL3 expression. Gene expression profiles of PB-CLL samples were grouped on the basis of the presence and absence of BLA. (A)
Gene expression signature of PB-CLL cells from BLA patients. PB-CLL samples were grouped based on a known prognostic indicator, presence
or absence of BLA, and gene expression profiles of these PB-CLL samples were correlated by using significant analysis of microarray analyses.
Comparison of expression profiles between PB-CLL with BLA (n = 9) and without BLA (n = 11) are shown. (B) Comparison of the expression of p-
SYK in CLL samples from patients with BLA (n = 4) and those without BLA (n = 5). (C) Expression of CCL3 transcripts in BM-CLL with poor chromo-
somal abnormalities (ChAb) (n = 6) versus good ChAb (n = 11) and LN-CLL with poor ChAb (n = 11) versus good ChAb (n = 3). (D) Relationship
between expression of CCL3 transcripts and time to treatment among the additional 40 PB-CLL samples using the Kaplan-Meier log-rank test.
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croenvironments. Although the GEP of
CLL cells from PB, BM and LN did not
cluster in a tissue-specific manner, LN-
CLL cells are far less heterogeneous than
GEP of PB-CLL and BM-CLL, as evi-
denced by the number of clusters in Fig-
ure 2A. Our findings are consistent with
the LN microenvironment providing
chronic stimulation via the BCR and
BAFF/ APRIL, which are critical for the
growth and survival of CLL cells. Our ob-
servation is consistent with the recent
findings by Herishanu et al. (18) showing
that the BCR signaling pathway is acti-
vated at LN sites and is likely a major
pathogenetic mechanism of CLL progres-
sion (29,30,41,42). We validated this obser-
vation by measuring levels of the kinase
SYK, which is a key in BCR signaling
using qRT-PCR and immunohistochem-
istry. Unlike Herishanu et al., our study
analyzes PB, BM and LN cells from differ-
ent patients, uses TCL1 transgenic mice
and correlates GEP with prognostic
groups. Despite using CLL cells from dif-
ferent sites from different patients, we ob-
served similar findings that BCR signaling
molecules are overexpressed in LN-CLL,
indicating that LN tissue sites play a
prominent role in influencing the gene
signature. Additionally, our studies also
observed that BAFF/APRIL- related genes
were also enriched in LN-CLL cells. These
genes have been shown to promote cell
survival and adverse prognosis in CLL
(31,43). These observations suggest that
LN sites provide signals for chronic acti-
vation of CLL cells. Expression of p-SYK
(key player of BCR signaling pathway)
and p-P65 (key molecule of NF-κB path-
way) in the lymphoid compartment was
validated by using LN samples of patients
and the Eμ-TCL1 mouse model.
Although certain interactions were spe-
cifically observed in LNs, molecules of
other major pathways, for example, NF-κB
and MAPK pathways (44), were constitu-
tively active in all tissue sites, indicating
that they may be responsible for sur-
vival/proliferation of CLL cells regardless
of anatomic location. Chemokine lig-
ands/receptors are being investigated ex-
tensively to better understand the migra-
tion of CLL cells. We observed that CCR7,
CXCR5 and CXCR4 were overexpressed
by PB-CLL, and their respective cognate
ligands CCL21 and CXCL13 were ex-
pressed by LN and CXCL12 in BM sites.
Upregulation of CCR7 was shown to facil-
itate the migration of CLL cells (32) and,
similarly, it is also facilitated by the inter-
action of the CXCR4-CXCL12 axis in CLL
(33,34). These observations indicate that
distinct microenvironments express differ-
ent ligands for interaction with tumor
cells. Interestingly, CCL3 was expressed by
all three types of CLL cells. CCL3 is
known to express at high levels in CLL
cells when cocultured on stroma (9,35)
and does attract T cells and follicular den-
dritic cells, thus indicating that CCL3 is
crucial for CLL cells in different microen-
vironments, probably to form clusters
with other cell types. We observed that
high expression of CCL3 was associated
with the poor outcome groups in BM and
LN, suggesting its role in disease progres-
sion. Consistent with these findings,
higher CCL3 expression was also associ-
ated with a shorter time to treatment in PB
cases. Furthermore, higher expression of
CCL21 and CXCL13 was observed in the
LN-CLL. These chemokine ligands are
known to be expressed by CLL as well as
other stromal cells, and thus a very high
expression may be partially contributed
because of some (<10%) contaminating
stromal cells in our LN-CLL preparation.
Interestingly, an immune suppressive
signature was also observed in CLL cells
from LN sites as previously reported by
Sasaki et al. (36) in acute-type adult T-cell
leukemia. Among the key tolerogenic
genes, CAV1, IFI16 and IDO1 were signifi-
cantly overexpressed in LN-CLL com-
pared with PB-CLL or BM-CLL. Although
LN is an appropriate place for immune
surveillance and generation of immune re-
sponse, it seems to provide CLL cells with
a supportive home. One explanation for
this phenomenon is that the immune-sup-
pressive gene signature expressed by CLL
cells creates immune dysfunction in the
LN site and, thus, may contribute to im-
mune evasion of CLL cells in this site.
These genes may play a crucial role in
modulating T-cell behavior and immune
synapse formation for the benefit of CLL
cells (38,39). Because BLA is used as a
marker of aggressive disease (21), we cor-
related GEPs with the presence and ab-
sence of BLA in PB. Interestingly, BCR sig-
naling genes including SYK, BTK, CD79b
and BLNK were overexpressed in PB-CLL
from patients with BLA. Furthermore,
genes related to hedgehog signaling,
chemokines, BAFF/APRIL and MAPK
signaling were also overexpressed in PB-
CLL from BLA patients (Figure 5A). Thus,
the gene expression signature of PB-CLL
cells from patients with BLA resembles
that of LN-CLL, suggesting that these PB-
CLL cells share a close and expected rela-
tionship with the LN-CLL cells. This result
is in accord with the recent reports that
quiescent PB-CLL cells are similar to pro-
liferating B cells of LN pseudofollicles (19),
and a dynamic relationship exists between
quiescent PB-CLL cells with the lymphoid
microenvironment (37). Similarly, overex-
pression of BCR signaling molecules was
also observed in LN and BM samples
from poor prognostic groups, although the
number of samples in each prognostic
group was smaller in these sites.
The importance of the microenviron-
ment has also been demonstrated by in
vitro systems wherein CLL cells sur-
vive/proliferate in the presence of stro-
mal cells (25). In concordance with other
studies, our in vitro stromal cultures pro-
moted survival and proliferation of CLL
cells. Because the microenvironment reg-
ulates the growth of CLL cells by regulat-
ing expression of key genes (45), we stud-
ied expression of a few NF-κB–associated
genes in CLL cells cocultured on stromal
cells. In this study, CLL cells cultured on
stroma upregulated NF-κB–associated
genes IL6, BCL2 and TRAF1, thus rein-
forcing the importance of the microenvi-
ronment in regulating gene expression.
CONCLUSION
We have summarized our results and
their possible interpretation in a hypothet-
ical model of survival/proliferation and
migration among PB-CLL, BM-CLL and
LN-CLL (Figure 6), where it is shown that
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PB-CLL cells use various MAPK and 
NF-κB target molecules for survival/
 proliferation in PB and use CCR7 and
CXCR5 chemokine receptors for their 
migration toward the LN microenviron-
ment, mediated by their cognate ligands
CCL21 and CXCL13, which are expressed
by LN-CLL. In the LN, CLL cells secrete
the chemokine ligand CCL3 to attract 
T cells and stromal cells. The interactions
of CLL cells and stroma lead to the activa-
tion of BCR and BAFF/APRIL signaling,
which in turn activates MAPK- and 
NF-κB–associated molecules. PB-CLL cells
express chemokine receptor CXCR4, and
its cognate ligand CXCL12/SDF-1 is se-
creted by BM stroma, thereby influencing
the migration of PB-CLL cells to the BM.
In the BM, CLL cells express CCL3 to at-
tract T cells and stromal cells; this interac-
tion activates expression of NF-κB and
MAPK molecules in BM-CLL cells, includ-
ing v-rel avian reticuloendotheliosis viral
oncogene homolog A (RELA), nuclear fac-
tor of kappa light polypeptide gene en-
hancer in B-cells inhibitor, beta (NF-κBIB)
and BCL2- related protein A1 (BCL2A1),
for survival/proliferation. Together our
results suggest that interactions between
the LN microenvironment and CLL cells
lead to the survival, proliferation and mi-
gration of CLL cells while inducing the
host immune suppression that results in
CLL progression. Overall, our study facili-
tates better understanding of the pathobi-
ology of CLL and also lays the foundation
for additional studies to eventually develop
improved therapy for CLL by targeting
Btk, Syk, Bcl2 and other identified key
molecules. Importantly, these molecules
are overexpressed in LN-CLL cells, which
suggests that targeting these molecules/
LN-CLL cells residing in LN will improve
better chances of disease remission.
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Figure 6. A hypothetical model of molecular determinants of CLL cell survival, proliferation and migration in the PB, BM and LN microenvi-
ronments. Peripheral blood: CLL cells use different NF-κB– and MAPK-associated genes for survival and proliferation. PB-CLL cells express
chemokine receptors, which stimulate PB-CLL migration to the LN or BM. Lymph nodes: CLL cells attract stromal cells to form a suitable
microenvironment. Here, CLL cells undergo chronic activation via the BCR, BAFF/APRIL, NF-κB, MAPK and PI3K/Akt pathways, which leads
to survival and proliferation. In addition, because of expression of a tolerogenic signature in LN-CLL, the immune cells are tolerogenic and
unable to identify or kill CLL cells in LNs; Bone marrow: CLL cells attract stromal cells to form a suitable microenvironment. Here, CLL cells
use different NF-κB and MAPK pathway genes for survival and proliferation.
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